By Deena Beasley (Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into ...

The Chinese scientist who was imprisoned for secretly creating the world’s first genetically-engineered babies has claimed he ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR ...

Shares of Prime Medicine ( PRME -0.25%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

Using gene editing with CRISPR-Cas9, the team has been able to study these proteins without altering ... Dec. 13, 2024 — Microorganisms produce a wide variety of natural products that can be ...

ECURE previously announced that the first patient dosed with ECUR-506 for OTC deficiency achieved a complete clinical ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...